Latest News on CAPR

Financial News Based On Company


Advertisement
Advertisement

Capricor Therapeutics, Inc. (4LN2.DE) cash flow

https://uk.finance.yahoo.com/quote/4LN2.DE/cash-flow/
This article provides a detailed look at Capricor Therapeutics, Inc.'s cash flow statements for annual and quarterly periods ending December 31, 2025. It presents data for operating, investing, and financing activities, along with supplemental cash flow information like free cash flow to firm and capital expenditure. The financial statements have been updated with a new layout offering more detail.

Key facts: FDA Extends Deramiocel Review; Capricor Reports Q3 Loss

https://www.tradingview.com/news/tradingview:05e7fcd3c8c5e:0-key-facts-fda-extends-deramiocel-review-capricor-reports-q3-loss/
The FDA has extended its review of Capricor Therapeutics' deramiocel application by three months due to a major amendment involving HOPE-3 data and efficacy analyses, pushing the decision date past the original Nov. 22. Concurrently, Capricor Therapeutics reported a Q3 loss of $0.73 per share with no revenue, alongside a significant increase in operating costs and a 10% workforce reduction.

Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel - Capricor Therapeutics (NAS

https://www.benzinga.com/trading-ideas/movers/26/11/63383853/capricor-stock-in-focus-ahead-of-fda-decision-on-duchenne-therapy-deramiocel
Capricor Therapeutics (NASDAQ:CAPR) shares are gaining as the FDA's decision on its Duchenne muscular dystrophy therapy, deramiocel, approaches on November 22. The FDA extended its review after a major amendment to the Biologics License Application, which included two-year open-label extension data from the Phase 3 HOPE-3 trial showing a 76% slower decline in upper limb impairment. Despite a wider Q3 loss due to pre-commercial and manufacturing scale-up spending, the company maintains sufficient cash to fund operations for at least the next 12 months.

Capricor Stock Rises: What's Going On?

https://www.benzinga.com/trading-ideas/movers/26/11/63349879/capricor-stock-rises-whats-going-on
Capricor Therapeutics (NASDAQ:CAPR) shares are rising as traders anticipate the FDA's decision on its Duchenne muscular dystrophy therapy, deramiocel, with a PDUFA target date of November 22, 2026. The company's Biologics License Application is currently under FDA review. Positive Phase 3 HOPE-3 results showed improved upper-limb function and potential cardiac benefits, further strengthened by recognition from the American Heart Association and The Lancet.

FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week

https://finance.yahoo.com/healthcare/articles/fda-decision-watch-capricor-dmd-100958121.html
The FDA is set to announce decisions on three drug applications this week, involving Capricor Therapeutics (CAPR), Savara (SVRA), and privately held Beren Therapeutics, following a Complete Response Letter for Summit Therapeutics. Capricor's Duchenne muscular dystrophy (DMD) therapy, Deramiocel, faces a critical approval decision after a previous rejection and an unfavorable advisory panel vote, with analysts divided on its prospects. Savara's Molbreevi, targeting a rare lung disease, has blockbuster potential according to JPMorgan, with its FDA decision expected on November 22, while Beren's Adrabetadex for a rare nervous system disorder also awaits a verdict.
Advertisement

Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones

https://news.stocktradersdaily.com/news_release/39/Precision_Trading_with_Capricor_Therapeutics_Inc._CAPR_Risk_Zones_111626064602_1794829562.html
This report provides a precision trading analysis for Capricor Therapeutics Inc. (CAPR), outlining three distinct AI-generated trading strategies: Position Trading (Long), Momentum Breakout (Breakout), and Risk Hedging (Short). The analysis highlights a potential shift from strong near and mid-term sentiment to a weak long-term outlook, identifying key entry, target, and stop loss levels for each strategy.

How reimbursement rules can break your deal: Lessons from Capricor Therapeutics, Inc. v. NS Pharma, Inc.

https://www.winstontaylor.com/insights/how-reimbursement-rules-can-break-your-deal-lessons-from-capricor-therapeutics-inc-v-ns-pharma-inc
This article analyzes the legal dispute between Capricor Therapeutics, Inc. and NS Pharma, Inc., highlighting how the deal's structure failed to account for Medicare Part B reimbursement mechanics. The core issue is that NS Pharma's commercialization costs and milestone obligations required a markup that Medicare's ASP+6% reimbursement model, based on Capricor's transfer price, could not accommodate, leading to financial disincentives for healthcare providers. The case underscores the critical need for life sciences companies to thoroughly model reimbursement economics for provider-administered therapies before finalizing commercialization agreements.

Roth Capital maintains Capricor Therapeutics at Neutral, raises price target to $10.50 from $7

https://www.tradingview.com/news/tradingview:5cfd23218ece3:0-roth-capital-maintains-capricor-therapeutics-at-neutral-raises-price-target-to-10-50-from-7/
Roth Capital has reiterated its "Neutral" rating for Capricor Therapeutics (CAPR) and increased its price target from $7 to $10.50, representing a 50% jump. This new price target suggests a 2.5% upside from the stock's closing price of $10.24 on November 12.

Capricor Files Q3 2026 Results Before Deramiocel FDA Decision

https://www.clinicaltrialvanguard.com/news/capricor-files-q3-2026-results-before-deramiocel-fda-decision/
Capricor Therapeutics filed its Q3 2026 earnings 8-K on November 10, just twelve days before the FDA's November 22 PDUFA date for deramiocel, its cell therapy for Duchenne muscular dystrophy. The filing itself is procedural, referencing a press release but not reproducing financial figures, though it confirms CEO Linda Marbán's sign-off. The key factor is the FDA's decision on deramiocel's approval and the scope of its labeled indication, which will determine its commercial reach.

Capricor Therapeutics, Inc. Stock 12‑Month Price Target Cut to $26.67, Implies 201% Upside

https://www.tradingview.com/news/tradingview:9dd15ac5136a7:0-capricor-therapeutics-inc-stock-12-month-price-target-cut-to-26-67-implies-201-upside/
Capricor Therapeutics, Inc. (CAPR) has seen its average 12-month price target cut slightly from $27 to $26.67 by analysts, though this still implies a substantial 201% potential upside based on the Nov. 10 closing price. The consensus rating for CAPR remains a "Buy" from 9 covering analysts, with 5 "Buys" and 4 "Holds."
Advertisement

Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss

https://www.benzinga.com/trading-ideas/movers/26/11/63145272/capricor-stock-rises-despite-a-wider-than-expected-q3-loss
Capricor Therapeutics Inc. (NASDAQ: CAPR) shares are trading higher despite reporting a wider-than-expected loss of 73 cents per share for the third quarter. The company announced significant progress on its regulatory filing and launch readiness for deramiocel, its Duchenne muscular dystrophy treatment, which has an FDA decision date of Nov. 22, 2026. The stock is up over 15% following these updates.

Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...

https://uk.finance.yahoo.com/news/capricor-therapeutics-inc-capr-q3-070838897.html
Capricor Therapeutics Inc. held its Q3 2026 earnings call, reporting no revenue but a strong cash position of $198.5 million. The company is nearing its PDUFA date of November 22, 2026, for Deramiocel, which met its primary endpoint in the HOPE-3 trial and showed robust results across analyses. Despite an ongoing contractual dispute with NS Pharma and increased operating expenses, Capricor is preparing for independent commercialization, with manufacturing facilities ready for launch.

CAPR: HOPE-3 strengthened the Deramiocel case as FDA review and launch preparations advanced

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4561110:0-capr-hope-3-strengthened-the-deramiocel-case-as-fda-review-and-launch-preparations-advanced/
Capricor Therapeutics (CAPR) saw its Deramiocel case strengthened by HOPE-3 and integrated data as the FDA review approached its November 22 target date. The company reported $198.5M in cash and marketable securities at quarter-end, with launch readiness efforts progressing. This information is based on the company's Q3 2026 Audio Transcript from November 10, 2026.

Capricor Therapeutics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:b9ee60cef094b:0-capricor-therapeutics-q3-earnings-call-highlights/
Capricor Therapeutics is preparing for a potential launch of Deramiocel for Duchenne muscular dystrophy, with an FDA decision expected on November 22. The company reported a wider third-quarter loss due to pre-commercial activities and manufacturing scale-up, while also addressing a contractual dispute with a distributor. Capricor's CEO highlighted positive trial data and manufacturing readiness for independent commercialization if approved.

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

https://stocktwits.com/news-articles/markets/equity/capr-stock-rallies-after-hours-as-capricor-reaffirms-deramiocel-confidence-ahead-of-nov-22-decision-says-application-in-final-review/cNGuyehR9J0
Capricor Therapeutics (CAPR) saw its stock rally after hours as the company reaffirmed confidence in its Duchenne muscular dystrophy (DMD) therapy, deramiocel, during its third-quarter earnings call. The FDA is set to decide on deramiocel's approval for preserving upper-limb function in DMD patients by November 22, with Capricor stating its Biologics License Application is in final review. Despite a widened net loss and increased operating expenses, the company is advancing launch preparations and pursuing independent commercialization, while also reducing its workforce by 10%.
Advertisement

Capricor Shares Rebound After Hours as CEO Signals Deramiocel BLA Nears FDA Verdict

https://finance.biggo.com/news/ea30ec01-7545-4f6e-b5d6-fbffe73250ad
Capricor Therapeutics shares rose after hours as CEO Linda Marbán announced that the Biologics License Application for deramiocel is in the final stages of FDA review, with a decision expected on November 22. The application focuses on preserving upper-limb function in Duchenne muscular dystrophy patients over nine, following previous rejections for cardiomyopathy. The company reported a significant third-quarter net loss but holds substantial cash and has scaled back operations in preparation for a potential solo launch.

Capricor Misses As Pre-Launch Spending Climbs; Data Package Is Rebuilt, But The November 22 FDA Decision Now Rests On A Narrower Indication

https://finviz.com/news/420715/capricor-misses-as-pre-launch-spending-climbs-data-package-is-rebuilt-but-the-november-22-fda-decision-now-rests-on-a-narrower-indication
Capricor Therapeutics reported a third-quarter loss of $0.73 per share, missing estimates, as pre-launch spending on Deramiocel climbed. The company enters a binary FDA decision on November 22, 2026, with a stronger data package but a narrower proposed indication for upper-limb impairment in patients over nine, following a previous negative advisory committee vote. This situation heightens the stakes for the upcoming FDA decision given accelerating spending and declining cash reserves.

Earnings call transcript: Capricor Therapeutics posts wider Q3 2026 loss

https://www.investing.com/news/transcripts/earnings-call-transcript-capricor-therapeutics-posts-wider-q3-2026-loss-93CH-5017129
Capricor Therapeutics reported a wider-than-expected Q3 2026 loss of $0.73 per share, significantly missing analyst estimates of $0.13. Despite this, the company confirmed sufficient cash for at least 12 months of operations and is preparing for a potential U.S. launch of its lead therapy, deramiocel, for Duchenne muscular dystrophy, with an FDA target action date of November 22, 2026. Management expressed confidence in deramiocel's clinical data, manufacturing readiness, and its ability to proceed with an independent launch despite an ongoing dispute with NS Pharma.

Capricor Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63126898/capricor-therapeutics-q3-2026-earnings-call-transcript
Capricor Therapeutics is in the final stages of FDA review for its BLA for deramiocel, targeting upper limb impairment in Duchenne muscular dystrophy patients, with a PDUFA date of November 22, 2026. The company submitted a major amendment including 24-month open-label extension data from HOPE-3 and integrated efficacy data, reporting a net loss of $42.7 million for Q3 2026 due to pre-commercial activities. Capricor is preparing for commercial launch with a ready San Diego manufacturing facility and is managing a contractual dispute with NS Pharma.

Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.stocktitan.net/news/CAPR/capricor-therapeutics-reports-third-quarter-2026-financial-results-6i5s9jv59n1z.html
Capricor Therapeutics reported a wider net loss of $42.7 million for Q3 2026, or $0.73 per share, compared to $24.6 million in Q3 2025, with no revenue recognized. The FDA's target action date for their Duchenne muscular dystrophy treatment, Deramiocel, was extended to November 22, 2026, following a major amendment to their Biologics License Application. Despite increased pre-commercial and manufacturing spending, the company expects its current financial resources to fund operations for at least the next twelve months.
Advertisement

CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retail’s Attention Remains Firmly Fixed On Nov. 22 FDA Decision For Deramiocel

https://www.tradingview.com/news/stocktwits:ea8fd99ce094b:0-capr-stock-edges-higher-ahead-of-q3-earnings-but-retail-s-attention-remains-firmly-fixed-on-nov-22-fda-decision-for-deramiocel/
Capricor Therapeutics (CAPR) saw its stock rise ahead of its Q3 earnings report, with investors focusing on the company’s cash position and an upcoming FDA decision on its Duchenne muscular dystrophy drug, Deramiocel, on November 22. Analysts expect a narrower Q3 net loss, and retail investors are highly bullish on FDA approval, with some hoping for a Priority Review Voucher (PRV) that could significantly extend the company's financial runway. Oppenheimer maintains an 'Outperform' rating, citing a greater likelihood of approval than suggested by the current share price.

US Stock Futures Mixed As Investors Await CPI Data — AMD, CRWV, RKLB Stocks In Focus

https://www.tradingview.com/news/stocktwits:c5dbf6321094b:0-us-stock-futures-mixed-as-investors-await-cpi-data-amd-crwv-rklb-stocks-in-focus/
U.S. stock futures are mixed as investors await the October CPI report and key earnings from companies like CoreWeave, D-Wave Quantum, and Capricor Therapeutics. Oil prices have retreated due to easing Middle East tensions. Advanced Micro Devices (AMD) and Rocket Lab (RKLB) are also in focus, with AMD gaining bullish analyst upgrades and Rocket Lab securing significant Neutron missions despite a wider-than-expected Q3 loss.

CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision

https://newsable.asianetnews.com/markets/capr-stock-rises-after-deramiocel-cardiac-data-wins-american-heart-association-award-ahead-of-fda-decision-articleshow-ni9wdma
Shares of Capricor Therapeutics (CAPR) rose 8% after its Deramiocel cardiac results from the HOPE-3 trial received the Outstanding Research Award in Pediatric Cardiology. This award adds momentum ahead of the FDA's decision on approving Deramiocel for Duchenne muscular dystrophy (DMD) by November 22. The data highlighted potential benefits on heart function and scarring in DMD patients, a disease where cardiomyopathy is the leading cause of death.

In patients with Duchenne and heart disease, heart function was 2.8 percentage points higher than placebo.

https://www.stocktitan.net/news/CAPR/capricor-s-hope-3-phase-3-cardiac-results-for-deramiocel-win-jwgtlkrw1h7q.html
Capricor Therapeutics announced that new cardiac data from its HOPE-3 Phase 3 trial for Deramiocel in Duchenne muscular dystrophy received an American Heart Association pediatric cardiology research award. While the overall cardiac endpoint missed statistical significance, a prespecified subgroup of patients with cardiomyopathy showed a 2.8-percentage-point advantage in heart pumping function, and scar imaging indicated fewer newly scarred heart segments. The Biologics License Application for Deramiocel remains under FDA review with a target action date of November 22, 2026.

Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel

https://www.globenewswire.com/news-release/2026/11/09/3398455/0/en/capricor-s-hope-3-phase-3-cardiac-results-for-deramiocel-win-american-heart-association-outstanding-research-award-in-pediatric-cardiology.html
Capricor Therapeutics announced that cardiac results from its HOPE-3 Phase 3 trial of Deramiocel for Duchenne muscular dystrophy (DMD) received an Outstanding Research Award in Pediatric Cardiology from the American Heart Association. The data showed promising improvements in heart function, particularly in patients with cardiomyopathy, and slower progression of heart scarring. The company's Biologics License Application for Deramiocel is currently under FDA review with a PDUFA target action date of November 22, 2026.
Advertisement

Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology

https://www.manilatimes.net/2026/11/09/tmt-newswire/globenewswire/capricors-hope-3-phase-3-cardiac-results-for-deramiocel-win-american-heart-association-outstanding-research-award-in-pediatric-cardiology/2465374
Capricor Therapeutics announced that its HOPE-3 Phase 3 trial cardiac results for Deramiocel in Duchenne muscular dystrophy (DMD) received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. The study showed positive effects on heart function and reduced scarring, particularly in patients with cardiomyopathy, indicating Deramiocel's potential as a vital treatment for DMD-related cardiac issues. The company awaits FDA review completion for its Biologics License Application, with a target action date of November 22, 2026.

Technical Reactions to CAPR Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/20/Technical_Reactions_to_CAPR_Trends_in_Macro_Strategies_110626074202_1793968922.html
This report from Stock Traders Daily analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR), identifying a mid-channel oscillation pattern and a strong near to mid-term sentiment that could shift a weak long-term outlook. It presents three AI-generated trading strategies—Position Trading (long), Momentum Breakout (breakout), and Risk Hedging (short)—with specific entry, target, and stop levels. The analysis also highlights an exceptional 241.0:1 risk-reward short setup targeting significant downside.

Capricor Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27, Implies 228% Upside

https://www.tradingview.com/news/tradingview:a1727224d0a70:0-capricor-therapeutics-inc-stock-12-month-price-target-raised-to-27-implies-228-upside/
Capricor Therapeutics, Inc. (CAPR) has seen its average 12-month price target raised from $23.67 to $27 by 5 analysts, with a range of $7 to $54 per share. This new target suggests a potential upside of approximately 228% based on the November 3 closing price. The consensus rating for CAPR remains "Buy" among 10 covering analysts, with 4 "Buys" and 6 "Holds."

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

https://finance.yahoo.com/healthcare/articles/capricor-therapeutics-report-third-quarter-140000340.html
Capricor Therapeutics announced it will release its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. The biotechnology company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Capricor Therapeutics focuses on developing cell and exosome-based therapies for rare diseases, with its lead product candidate, Deramiocel, in late-stage development for Duchenne muscular dystrophy.

CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel

https://stocktwits.com/news-articles/markets/equity/capr-stock-rises-as-clinical-trial-investigators-write-to-fda-urging-approval-for-deramiocel/cNGX1b1R9d0
Shares of Capricor Therapeutics (CAPR) surged by approximately 14% after 28 physician-scientists involved in the HOPE-3 trial wrote to the FDA, urging approval for the company's Duchenne muscular dystrophy therapy, Deramiocel. The FDA is expected to make a decision by November 22, and investigators highlighted the drug's efficacy in preserving upper-limb function, noting the critical stakes for patients who cannot walk. This public letter adds significant momentum as the company navigates a complex regulatory path, having previously faced rejections for a broader cardiomyopathy indication.
Advertisement

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

https://www.globenewswire.com/news-release/2026/11/03/3394272/0/en/capricor-therapeutics-to-report-third-quarter-2026-financial-results-and-provide-recent-corporate-update-on-november-10.html
Capricor Therapeutics announced it will release its third-quarter 2026 financial results after market close on Tuesday, November 10, 2026. The biotechnology company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Details for accessing the call and webcast are provided in the announcement.

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

https://www.stocktitan.net/news/CAPR/capricor-therapeutics-to-report-third-quarter-2026-financial-results-o0682ldyha3y.html
Capricor Therapeutics (NASDAQ: CAPR) announced it will release its third-quarter 2026 financial results after market close on November 10, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. A replay of the webcast will be available on the Investors section of Capricor’s website.

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

https://newsable.asianetnews.com/markets/fda-decision-watch-regeneron-and-roche-s-autoimmune-drugs-capricor-s-dmd-therapy-in-spotlight-articleshow-3rxzeqc
November 2026 brings several significant FDA decisions, with Regeneron and Alnylam's Cemdisiran for generalized myasthenia gravis, Roche's Gazyva for primary membranous nephropathy, and Capricor Therapeutics' Deramiocel for DMD all under review. Cemdisiran and Gazyva have shown promising Phase 3 trial results, with Gazyva potentially becoming the first FDA-approved treatment for its indication. Roche also awaits a decision on its breast cancer drug, Giredestrant, which has a projected peak annual sales exceeding CHF3 billion.

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

https://stocktwits.com/news-articles/markets/equity/capr-stock-fda-decision-month-retail-approval-capricor-launch-team-hiring/cNG9lpVR92i
Capricor Therapeutics (CAPR) shares rose over 4% as retail investors speculated that recent job postings for commercial and patient services roles indicated an upcoming FDA approval for its Duchenne muscular dystrophy treatment, Deramiocel. The FDA's target decision date for Deramiocel is November 22, after an extension to review additional data focusing on preserving arm and hand function. Despite a previous advisory panel voting against the treatment's effectiveness for heart-related indications, the company is preparing for a potential launch.

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

https://finance.yahoo.com/healthcare/articles/capr-stock-rallies-fda-decision-042158716.html
Shares of Capricor Therapeutics (CAPR) surged as retail investors interpreted recent job postings for launch-related roles as an indicator of potential FDA approval for its Duchenne muscular dystrophy treatment, Deramiocel. The FDA's decision deadline is November 22, following an extension to review additional data focused on preserving arm and hand function. Despite a previous advisory panel vote against the treatment's effectiveness for a heart-related indication, the company remains optimistic about its upper-limb endpoint data.
Advertisement

12 Health Care Stocks Moving In Friday's After-Market Session

https://www.benzinga.com/trading-ideas/movers/26/10/62760544/12-health-care-stocks-moving-friday-s-after-market-session
This article details the performance of 12 health care stocks during Friday's after-market session, highlighting both gainers and losers. Inovio Pharmaceuticals saw a significant increase of 292.6%, while Precigen experienced a substantial decrease of 26.5%. The movements are often tied to recent earnings releases or other company-specific news.

Capricor Therapeutics, Inc. (CAPR) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/CAPR/seasonality/
This article provides a seasonal returns chart for Capricor Therapeutics, Inc. (CAPR), showing average monthly price returns from 2016 to 2026. It also displays real-time stock price data, after-hours trading information, and a list of related tickers in the biotechnology and pharmaceutical sectors.

Capricor Therapeutics, Inc. Estimates – NASDAQ:CAPR

https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-estimates/
The article provides an overview of Capricor Therapeutics, Inc. (NASDAQ: CAPR) financial data and analyst estimates available on TradingView. It highlights sections for exploring income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with average, high, and low estimates and visualize trends over time. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.

Capricor Therapeutics, Inc. Cash Flow – XETR:4LN2

https://www.tradingview.com/symbols/XETR-4LN2/financials-cash-flow/
Capricor Therapeutics Inc. (XETR:4LN2) reported a free cash flow of −32.74M EUR for Q2 2026. For the full year 2025, the company's free cash flow was −69.42M EUR, with operating cash flow at −59.44M EUR. The financial data includes operating, investing, and financing activities, with detailed cash flow information available annually and quarterly.

We're Keeping An Eye On Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

https://www.moomoo.com/news/post/1001531384/we-re-keeping-an-eye-on-capricor-therapeutics-nasdaq-capr
Capricor Therapeutics has a high cash burn rate relative to its cash reserves, with only about two years of cash runway remaining. While the company recently raised $100 million, which will extend its runway, investors should monitor its cash flow closely as it continues to operate at a loss. Despite the cash concerns, the company has seen positive share price momentum recently.
Advertisement

CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy

https://stocktwits.com/news-articles/markets/equity/capr-stock-on-track-for-worst-week-ever-after-regulatory-setback-for-dmd-therapy/cZN4ib6RJPH
Capricor Therapeutics (CAPR) stock is experiencing its worst week ever, plummeting nearly 80% due to regulatory setbacks for its Duchenne muscular dystrophy treatment, Deramiocel. An FDA advisory committee voted against the therapy's effectiveness for heart problems linked to DMD, despite the company's continued confidence and the upcoming final FDA decision on August 22. Retail traders remain largely bullish, anticipating the FDA's ultimate ruling.

Voting power over 1.67M Capricor (CAPR) shares is shared by three reporting parties.

https://www.stocktitan.net/sec-filings/CAPR/schedule-13g-a-capricor-therapeutics-inc-amended-passive-investment-d-ad528085f02c.html
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended ownership disclosure for Capricor Therapeutics, Inc. (CAPR). Each entity reports shared voting and dispositive power over 1,669,083 shares, representing 2.9% of the class. The shares are held by entities under the voting control and investment discretion of Millennium Management LLC and/or other investment managers.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - Slideshow (NASDAQ:CAPR) 2026-10-13

https://seekingalpha.com/article/4953936-capricor-therapeutics-inc-capr-discusses-hopeminus-3-open-label-extension-data-and-deramiocel
Capricor Therapeutics, Inc. (CAPR) published a slide deck discussing HOPE-3 Open-Label Extension data and providing an update on Deramiocel for Duchenne Muscular Dystrophy. This information was released in conjunction with an event.

Capricor Therapeutics (CAPR) Short Interest & Short Float | Updated Oct 2026

https://www.marketbeat.com/stocks/NASDAQ/CAPR/short-interest/
This article provides an updated analysis of Capricor Therapeutics (CAPR) short interest and short float as of September 30, 2026. It details that 18.83 million shares, representing 35.66% of the public float, were sold short, marking a 4.35% decrease from the previous report. The short interest ratio stands at 4.5 days to cover, indicating moderate sentiment.

Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/analysts-expect-breakeven-for-capricor-therapeutics-inc-nasd-1
Analysts predict Capricor Therapeutics, Inc. (NASDAQ:CAPR) will reach breakeven by 2028, projecting a final loss in 2027 before generating US$7.7m in profits. This forecast requires an average annual growth rate of 67%. The company currently operates without debt, relying on shareholder funding, which reduces investment risk.
Advertisement

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

https://es.tradingview.com/news/marketbeat:370ab5dbd094b:0-capricor-highlights-two-year-deramiocel-data-as-fda-decision-nears/
Capricor Therapeutics has released updated two-year data for deramiocel in Duchenne muscular dystrophy (DMD) as the FDA's decision date for its biologics license application approaches on November 22. The company refined its proposed indication to focus on upper-limb impairment in patients older than 9 years, following an FDA Advisory Committee vote. Clinical data from the Phase III HOPE-3 study, including open-label extension results, showed a statistically and clinically meaningful improvement in upper-limb function and a treatment benefit in cardiac function.

Capricor Therapeutics Stock Short Interest Falls to 37.37%

https://www.quiverquant.com/news/Capricor+Therapeutics+Stock+Short+Interest+Falls+to+37.37%25
Capricor Therapeutics (CAPR) saw its short interest fall to 37.37% of the float on September 15th, a decrease of 11.28% from August 31st, with 19,680,648 shares shorted. This indicates it would take short sellers nearly 6 days to cover their positions. Institutional investors have shown mixed activity, with more adding than decreasing shares, while insiders have engaged in sales but no purchases over the past six months.

Capricor Therapeutics, Inc. (CAPR) Options Chain - Yahoo Finance

https://ca.finance.yahoo.com/quote/CAPR/options/?date=1793318400&straddle=false&type=all
This page from Yahoo Finance provides detailed options chain data for Capricor Therapeutics, Inc. (CAPR), including both call and put options with an expiration date of October 30, 2026. It lists strike prices, last trade dates, last prices, bid/ask, change, volume, open interest, and implied volatility for various contracts. The stock was trading at $7.47, down 4.60% at close on October 12, with pre-market activity showing it at $7.32.

After a year on placebo, patients’ arm-function decline rate was 76% lower on treatment

https://www.stocktitan.net/news/CAPR/capricor-therapeutics-presents-positive-hope-3-open-label-extension-0dad7pk8k24n.html
Capricor Therapeutics announced positive open-label extension data from its HOPE-3 study for Deramiocel in Duchenne muscular dystrophy. Patients who switched from placebo to Deramiocel experienced a 76% slower decline in upper limb function. The data supports Deramiocel's biologics license application, with an FDA target action date of November 22, 2026.

What's Going On With Capricor Therapeutics Stock Monday?

https://www.benzinga.com/markets/biotech/26/10/62172412/whats-going-on-with-capricor-therapeutics-stock-monday
Capricor Therapeutics (NASDAQ: CAPR) presented new data from its HOPE-3 open-label extension study for Deramiocel, a treatment for Duchenne muscular dystrophy. Despite a previous FDA advisory panel's skepticism, the new data suggests a significant reduction in disease progression and outperformance of natural history predictions. The FDA's decision on Deramiocel is expected by November 22, and the stock was down 9.39% on Monday.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement